Indeed, IL-33 increases the number of Tregs when administered to mice prior to alloHCT; these IL-33–expanded Tregs prevent the activation of macrophages and reduce the number of effector T cells that damage GVHD target tissues (6). The gene discussed is IL33; the disease is graft versus host disease.